Outcome of Board meeting for Financial Results

Net loss reportedEBITDA margin compressionExceptional itemEmphasis of matterResults View source PDF Explain this filing

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹540.00

prior close

₹544.00

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.2%-1.8% vs market

Pharmaceuticals peers, median of 161sector+0.4%-1.9% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 1.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.2

10m

-4.0

15m

-4.2

30m

-1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5+0.2-1.8+0.4-1.9

Next day

-4.3-0.1-4.2+0.1-4.4

-4.8-1.5-3.3-0.4-4.4

-3.7-1.0-2.7+0.0-3.8

-5.1-0.4-4.6+1.2-6.3

-3.1+0.6-3.7+2.1-5.1

-3.5+2.3-5.8+1.1-4.6

15d

+2.4+3.5-1.1+1.4+1.0

+14.6+5.6+9.1+2.2+12.4

+27.2+9.5+17.7+7.9+19.3

+34.2+13.3+21.0+8.1+26.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 161Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Akums Drugs reported standalone PAT of ₹1,116.40 million for FY2026, down 30.7% from ₹1,609.98 million in FY2025. Revenue from operations grew marginally to ₹13,487.36 million from ₹13,117.84 million. The auditors issued an unmodified opinion but included an Emphasis of Matter regarding an Income Tax Department search and seizure operation (January 2025) and subsequent show cause notices, with impact not yet ascertainable. Exceptional items of ₹65.19 million were recognized due to changes in labour code and retrospective VDA arrears. The Board recommended a final dividend of ₹1 per share plus a special dividend of ₹2 per share. Changes in senior management were also approved.

Likely market impact

The significant PAT decline of ~31% despite marginal revenue growth signals margin compression and operational challenges. The unresolved Income Tax Department proceedings create regulatory uncertainty. The special dividend suggests management confidence, but investors should monitor the tax investigation outcome.